NeoGenomics' stock plummeted 7.73% during intraday trading on Tuesday, following the release of its fourth-quarter and full-year 2025 financial results.

The cancer diagnostics company reported a net loss of $10 million for the fourth quarter, which negatively impacted investor sentiment. Despite this bottom-line loss, NeoGenomics posted an adjusted earnings per share of $0.06, surpassing the Ibes estimate of $0.04.

The mixed earnings report has left analysts conflicted about the company's near-term prospects, contributing to the stock's decline as investors appeared to focus on the reported net loss.